Mural Oncology Q1 2024 net loss $30.9M, cash runway into Q4 2025 reaffirmed

Mural Oncology plc

2024-Q1 EPS reported -$1.84

Net loss $30.9M improved from $46.5M Q1 2023; R&D spend $26.9M down 33% YoY.
Cash, equivalents & marketable securities $231.7M as of March 31, 2024.
Nemvaleukin alfa registrational trials on track; ARTISTRY-7 interim OS data Q1 2025.
Less-frequent IV dosing trial for cutaneous melanoma enrolling; preliminary data H1 2025.
IL-18/IL-12 preclinical data presented at AACR; candidate nominations expected by end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Mural Oncology plc reported first quarter of 2024 results: net income Net loss was $30.9 million. Guidance reaffirmed.

Period: first quarter of 2024
Net income: Net loss was $30.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Mural Oncology plc (the "Company") issued a press release announcing the Company’s financial results for the three months ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.